PTAB grants IPR of Celgene patents after Kyle Bass challenge
28-10-2015
Photo: Courtesy of Celgene ( Celgene Logo, https://www.celgene.com/media-library/celgene-logo/)
Biopharmaceutical company Celgene has reiterated its stance on the inter partes review (IPR) petitions filed by hedge fund manager Kyle Bass and has hinted it will appeal against a recent unfavourable decision.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Celgene, Patent Trial and Appeal Board, PTAB, USPTO, Coalition for Affordable Drugs, inter partes reviews, patents, Kyle Bass
